INO 4802
Alternative Names: INO-4802; Pan-SARS-CoV-2 Synthetic DNA Vaccine - Inovio PharmaceuticalsLatest Information Update: 28 Jun 2025
At a glance
- Originator Inovio Pharmaceuticals
- Class COVID-19 vaccines; DNA vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (Parenteral, Injection)
- 29 Sep 2021 Immunogenicity data from preclinical studies in COVID-2019 infections presented at the IDWeek 2021 (IDW-2021)
- 12 May 2021 Inovio Pharmaceuticals plans the phase I/II IMPACT (INOVIO INO-4802 Multi-variant Pan-COVID-19 Vaccine Trial) trial for COVID-2019 infections (Prevention) in 2021